{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T12:30:48Z","timestamp":1791462648772,"version":"4.3.4"},"reference-count":62,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ymgme.2023.107526","type":"journal-article","created":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T22:29:44Z","timestamp":1674685784000},"page":"107526","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Transcriptomic characterization of clinical skeletal muscle biopsy from late-onset Pompe patients"],"prefix":"10.1016","volume":"138","author":[{"given":"Sofia","family":"Kinton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Dufault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mindy","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"George","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ymgme.2023.107526_bb0005","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/j.jpeds.2004.01.053","article-title":"Pompe disease in infants and children","volume":"144","author":"Kishnani","year":"2004","journal-title":"J. Pediatr."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107526_bb0010","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1542\/peds.112.2.332","article-title":"The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature","volume":"112","author":"van den Hout","year":"2003","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.ymgme.2023.107526_bb0015","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpeds.2005.11.033","article-title":"A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease","volume":"148","author":"Kishnani","year":"2006","journal-title":"J. Pediatr."},{"issue":"9646","key":"10.1016\/j.ymgme.2023.107526_bb0020","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe\u2019s disease","volume":"372","author":"van der Ploeg","year":"2008","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.ymgme.2023.107526_bb0025","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid \u03b1-glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ymgme.2023.107526_bb0030","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","article-title":"Early treatment with alglucosidase alfa prolongs long-term survival of infants with Pompe disease","volume":"66","author":"Kishnani","year":"2009","journal-title":"Pediatr. Res."},{"issue":"15","key":"10.1016\/j.ymgme.2023.107526_bb0035","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease","volume":"362","author":"Van der Ploeg","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107526_bb0040","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00415-016-8219-8","article-title":"Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis","volume":"264","author":"Schoser","year":"2017","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107526_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1750-1172-8-49","article-title":"Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study","volume":"8","author":"G\u00fcng\u00f6r","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2023.107526_bb0050","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/mt.2009.37","article-title":"Glycoengineered acid \u03b1-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease","volume":"17","author":"Zhu","year":"2009","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.ymgme.2023.107526_bb0055","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S1474-4422(21)00241-6","article-title":"Safety and efficacy of avalglucosidase alfa versus alglucosidase alfa in patients with late-onset Pompe disease (COMET): a phase 3, randomised, multicentre trial","volume":"20","author":"Diaz-Manera","year":"2021","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107526_bb0060","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s10545-010-9144-0","article-title":"Hearing loss in Pompe disease revisited: results from a study of 24 children","volume":"33","author":"van Capelle","year":"2010","journal-title":"J. Inherited Metab. Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107526_bb0065","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s00455-009-9252-x","article-title":"Oropharyngeal dysphagia in infants and children with infantile Pompe disease","volume":"25","author":"Jones","year":"2010","journal-title":"Dysphagia"},{"issue":"2","key":"10.1016\/j.ymgme.2023.107526_bb0070","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.ymgme.2017.04.014","article-title":"Cognitive and academic outcomes in long-term survivors of infantile-onset Pompe disease: a longitudinal follow-up","volume":"121","author":"Spiridigliozzi","year":"2017","journal-title":"Mol. Genet. Metab."},{"issue":"19","key":"10.1016\/j.ymgme.2023.107526_bb0075","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000008441","article-title":"Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease","volume":"93","author":"Harlaar","year":"2019","journal-title":"Neurology"},{"issue":"23","key":"10.1016\/j.ymgme.2023.107526_bb0080","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1212\/WNL.0000000000004711","article-title":"Long-term benefit of enzyme replacement therapy in Pompe disease","volume":"89","author":"Kuperus","year":"2017","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ymgme.2023.107526_bb0085","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.nmd.2018.12.004","volume":"29","author":"Pena","year":"2019","journal-title":"Neuromuscul. Disord."},{"issue":"5","key":"10.1016\/j.ymgme.2023.107526_bb0090","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1365-2990.2007.00839.x","article-title":"Adult-onset glycogen storage disease type 2: clinico-pathological phenotype revisited","volume":"33","author":"Schoser","year":"2007","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107526_bb0095","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1186\/1471-2105-9-559","article-title":"WGCNA: an R package for weighted correlation network analysis","volume":"9","author":"Langfelder","year":"2008","journal-title":"BMC Bioinform."},{"issue":"43","key":"10.1016\/j.ymgme.2023.107526_bb0100","doi-asserted-by":"crossref","first-page":"15545","DOI":"10.1073\/pnas.0506580102","article-title":"Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles","volume":"102","author":"Subramanian","year":"2005","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"W1","key":"10.1016\/j.ymgme.2023.107526_bb0105","doi-asserted-by":"crossref","first-page":"W191","DOI":"10.1093\/nar\/gkz369","article-title":"g:Profiler: a web server for functional enrichment analysis and conversions of gene lists (2019 update)","volume":"47","author":"Raudvere","year":"2019","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107526_bb0110","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2105-14-7","article-title":"GSVA: gene set variation analysis for microarray and RNA-Seq data","volume":"14","author":"H\u00e4nzelmann","year":"2013","journal-title":"BMC Bioinform."},{"issue":"12","key":"10.1016\/j.ymgme.2023.107526_bb0115","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1093\/bioinformatics\/btr260","article-title":"Molecular signatures database (MSigDB) 3.0","volume":"27","author":"Liberzon","year":"2011","journal-title":"Bioinformatics"},{"issue":"6","key":"10.1016\/j.ymgme.2023.107526_bb0120","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","article-title":"The molecular signatures database Hallmark gene set collection","volume":"1","author":"Liberzon","year":"2015","journal-title":"Cell Syst."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107526_bb0125","first-page":"123","article-title":"Pathology of skeletal muscle cells in adult-onset glycogenosis type II (Pompe disease): ultrastructural study","volume":"46","author":"Lewandowska","year":"2008","journal-title":"Folia Neuropathol."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107526_bb0130","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1007\/s13311-018-0655-y","article-title":"Pompe disease: from basic science to therapy","volume":"15","author":"Kohler","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.ymgme.2023.107526_bb0135","series-title":"American Journal of Medical Genetics Part C: Seminars in Medical Genetics","article-title":"Autophagy and mitochondria in Pompe disease: nothing is so new as what has long been forgotten","author":"Raben","year":"2012"},{"key":"10.1016\/j.ymgme.2023.107526_bb0140","series-title":"Reactome, R-HSA-432720","article-title":"Lysosome Vesicle Biogenesis","author":"Gillespie","year":"2009"},{"issue":"2","key":"10.1016\/j.ymgme.2023.107526_bb0145","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.molmed.2016.12.003","article-title":"Mitochondrial dysfunction and neurodegeneration in lysosomal storage disorders","volume":"23","author":"Plotegher","year":"2017","journal-title":"Trends Mol. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2023.107526_bb0150","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1080\/15548627.2015.1009779","article-title":"Defects in calcium homeostasis and mitochondria can be reversed in Pompe disease","volume":"11","author":"Lim","year":"2015","journal-title":"Autophagy"},{"issue":"3","key":"10.1016\/j.ymgme.2023.107526_bb0155","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ymgme.2012.05.004","article-title":"Transcriptional response to GAA deficiency (Pompe disease) in infantile-onset patients","volume":"106","author":"Palermo","year":"2012","journal-title":"Mol. Genet. Metab."},{"issue":"299","key":"10.1016\/j.ymgme.2023.107526_bb0160","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaa7322","article-title":"Immune-mediated pathology in Duchenne muscular dystrophy","volume":"7","author":"Rosenberg","year":"2015","journal-title":"Sci. Transl. Med."},{"issue":"12","key":"10.1016\/j.ymgme.2023.107526_bb0165","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/labinvest.3700484","article-title":"Characterization of pre- and post-treatment pathology after enzyme replacement therapy for pompe disease","volume":"86","author":"Thurberg","year":"2006","journal-title":"Lab. Investig."},{"issue":"10","key":"10.1016\/j.ymgme.2023.107526_bb0170","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.4049\/jimmunol.1101267","article-title":"IFN-\u03b3 promotes muscle damage in the mdx mouse model of Duchenne muscular dystrophy by suppressing M2 macrophage activation and inhibiting muscle cell proliferation","volume":"187","author":"Villalta","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymgme.2023.107526_bb0175","series-title":"NEO1 and NEO-EXT Studies: Long-Term Safety and Exploratory Efficacy of Repeat Avalglucosidase Alfa Dosing for 5.5 Years in Late-Onset Pompe Disease Patients (695)","author":"Dimachkie","year":"2020"},{"issue":"1\u20132","key":"10.1016\/j.ymgme.2023.107526_bb0180","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ymgme.2016.05.013","article-title":"Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: the EMBASSY study","volume":"119","author":"van der Ploeg","year":"2016","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2023.107526_bb0185","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.omtm.2020.05.026","article-title":"Enzyme replacement therapy can reverse pathogenic cascade in Pompe disease","volume":"18","author":"Meena","year":"2020","journal-title":"Mol. Therapy-Methods Clin. Develop."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107526_bb0190","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/jimd.12344","article-title":"Combined proteomic and lipidomic studies in Pompe disease allow a better disease mechanism understanding","volume":"44","author":"Sidorina","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107526_bb0195","doi-asserted-by":"crossref","first-page":"318","DOI":"10.4161\/auto.2984","article-title":"Autophagy and lysosomes in Pompe disease","volume":"2","author":"Fukuda","year":"2006","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.ymgme.2023.107526_bb0200","first-page":"45","article-title":"Role of autophagy in the pathogenesis of Pompe disease","volume":"26","author":"Raben","year":"2007","journal-title":"Acta Myol."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107526_bb0205","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/rej.2005.8.3","article-title":"Selective mitochondrial autophagy, or mitophagy, as a targeted defense against oxidative stress, mitochondrial dysfunction, and aging","volume":"8","author":"Lemasters","year":"2005","journal-title":"Rejuvenation Res."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107526_bb0210","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S0960-8966(98)00117-5","article-title":"Adult glycogenosis II with paracrystalline mitochondrial inclusions and Hirano bodies in skeletal muscle","volume":"9","author":"Fern\u00e1ndez","year":"1999","journal-title":"Neuromuscul. Disord."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107526_bb0215","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1074\/jbc.M112.419788","article-title":"Interleukin-6\/signal transducer and activator of transcription 3 (STAT3) pathway is essential for macrophage infiltration and myoblast proliferation during muscle regeneration","volume":"288","author":"Zhang","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107526_bb0220","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1152\/physrev.90100.2007","article-title":"Muscle as an endocrine organ: focus on muscle-derived interleukin-6","volume":"88","author":"Pedersen","year":"2008","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ymgme.2023.107526_bb0225","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0083-6729(08)00621-3","article-title":"Interleukin-6 and insulin resistance","volume":"80","author":"Kim","year":"2009","journal-title":"Vitam. Horm."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107526_bb0230","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.diabres.2004.11.007","article-title":"Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-\u03b1 and IL-6","volume":"69","author":"Park","year":"2005","journal-title":"Diabetes Res. Clin. Pract."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107526_bb0235","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1748-1716.2011.02281.x","article-title":"Skeletal muscle mass recovery from atrophy in IL-6 knockout mice","volume":"202","author":"Washington","year":"2011","journal-title":"Acta Physiol."},{"issue":"1","key":"10.1016\/j.ymgme.2023.107526_bb0240","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1006\/bbrc.1995.1168","article-title":"Muscle undergoes atrophy in association with increase of lysosomal cathepsin activity in interleukin-6 transgenic mouse","volume":"207","author":"Tsujinaka","year":"1995","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107526_bb0245","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/JES.0b013e3181f44f11","article-title":"Interleukin-6 as a key regulator of muscle mass during cachexia","volume":"38","author":"Carson","year":"2010","journal-title":"Exerc. Sport Sci. Rev."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107526_bb0250","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1249\/MSS.0b013e31822f94ac","article-title":"Muscular interleukin-6 and its role as an energy sensor","volume":"44","author":"Pedersen","year":"2012","journal-title":"Med. Sci. Sports Exerc."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107526_bb0255","doi-asserted-by":"crossref","first-page":"E616","DOI":"10.1152\/ajpendo.00150.2004","article-title":"Cytokine regulation of skeletal muscle fatty acid metabolism: effect of interleukin-6 and tumor necrosis factor-\u03b1","volume":"287","author":"Bruce","year":"2004","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107526_bb0260","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00415-012-6636-x","article-title":"Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review","volume":"260","author":"Toscano","year":"2013","journal-title":"J. Neurol."},{"issue":"9","key":"10.1016\/j.ymgme.2023.107526_bb0265","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/nrm1198","article-title":"Titin: properties and family relationships","volume":"4","author":"Tskhovrebova","year":"2003","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"9","key":"10.1016\/j.ymgme.2023.107526_bb0270","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1007\/s00415-013-6980-5","article-title":"Swiss national guideline for reimbursement of enzyme replacement therapy in late-onset Pompe disease","volume":"260","author":"Hundsberger","year":"2013","journal-title":"J. Neurol."},{"issue":"9","key":"10.1016\/j.ymgme.2023.107526_bb0275","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1007\/s00415-014-7402-z","article-title":"Cessation and resuming of alglucosidase alfa in Pompe disease: a retrospective analysis","volume":"261","author":"Hundsberger","year":"2014","journal-title":"J. Neurol."},{"issue":"12","key":"10.1016\/j.ymgme.2023.107526_bb0280","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1007\/s00415-018-9065-7","article-title":"36-months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe registry","volume":"265","author":"Scheidegger","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2023.107526_bb0285","first-page":"1","article-title":"The impact of interrupting enzyme replacement therapy in late-onset Pompe disease","author":"Wenninger","year":"2021","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.ymgme.2023.107526_bb0290","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/ene.15222","article-title":"Motor and respiratory decline in patients with late-onset Pompe disease after cessation of enzyme replacement therapy during COVID-19 pandemic","volume":"29","author":"Tard","year":"2022","journal-title":"Eur. J. Neurol."},{"issue":"11","key":"10.1016\/j.ymgme.2023.107526_bb0295","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1005752","article-title":"mixOmics: an R package for \u2018omics feature selection and multiple data integration","volume":"13","author":"Rohart","year":"2017","journal-title":"PLoS Comput. Biol."},{"issue":"3","key":"10.1016\/j.ymgme.2023.107526_bb0300","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/s41592-019-0686-2","article-title":"SciPy 1.0: fundamental algorithms for scientific computing in Python","volume":"17","author":"Virtanen","year":"2020","journal-title":"Nat. Methods"},{"issue":"03","key":"10.1016\/j.ymgme.2023.107526_bb0305","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1109\/MCSE.2007.55","article-title":"Matplotlib: a 2D graphics environment","volume":"9","author":"Hunter","year":"2007","journal-title":"Comp. Sci. Eng."},{"issue":"60","key":"10.1016\/j.ymgme.2023.107526_bb0310","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.21105\/joss.03021","article-title":"Seaborn: statistical data visualization","volume":"6","author":"Waskom","year":"2021","journal-title":"J. Open Source Software"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223001567?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719223001567?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T01:40:17Z","timestamp":1703295617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719223001567"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":62,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1096719223001567"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.107526","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Transcriptomic characterization of clinical skeletal muscle biopsy from late-onset Pompe patients","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2023.107526","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107526"}}